Geoffrey Hill, M.D., FRACP, FRCPA

Fred Hutchinson Cancer Center

Disclosure(s): Applied Molecular Transport: Grant/Research Support; Compass Therapeutics: Grant/Research Support; Generon Corporation: Advisor/Consultant; Heat Biologics: Grant/Research Support; iTeos Therapeutics: Advisor/Consultant, Grant/Research Support; Laevoroc Oncology: Grant/Research Support; NapaJen Pharma: Advisor/Consultant; Neoleukin Therapeutics: Advisor/Consultant; Serplus Technology: Grant/Research Support; Syndax Pharmaceuticals: Grant/Research Support

Poster(s):

• 491 - Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 631 - CMV Reactivation in Hematopoietic Cell Transplant Candidates: A Novel Risk Factor for Post-transplant Reactivation
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 2094 - A prospective multicenter study of HHV-6B genomic DNA and gene transcription in paired bronchoalveolar lavage fluid and blood from HCT recipients
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET